Sanofi beats top-line and bottom-line estimates; raises FY26 outlook
Sanofi reported Q3 Non-GAAP EPS of €3.55, beating estimates by €2.04, with revenue of €14.44B, up 16.2% Y/Y. Pharma launches sales rose 31.4% to €1.4B, driven by ALTUVIIIO, Ayvakit, and Rezurock. Dupixent sales increased 34.8% to €5.7B. The company raised its FY26 outlook.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to boost investor confidence and drive short-term price appreciation.
Market read
First-report earnings with material beats from a large-cap pharma; high relevance for traders.
What to watch
Potential headwinds from upcoming regulatory reviews or competitive pressures are not addressed in the release.
Background
Sanofi's Q3 earnings were released via a press release on Oct 30, 2026, highlighting significant beats and an upgraded FY26 outlook.
Ticker impact
Sanofi reported Q3 Non-GAAP EPS of €3.55 beating estimates by €2.04 and revenue of €14.44B beating by €1.12B, while raising its FY26 outlook.
upward pressure as the market prices in the earnings beat and higher FY26 guidance
Large-cap pharma with material beat and outlook raise typically triggers a short-term rally.
Market effects
Health care sector may see a lift as Sanofi's beat reinforces demand for pharma products.
European markets could open higher on the news of a major French pharma's strong results.
Positive earnings from a global pharma leader can support risk-on sentiment worldwide.
Counterpoint
If the beat is already priced in, the stock could face short-covering pullback later in the day.
Key entities
- companySanofi
French multinational pharmaceutical company.
